Literature DB >> 1578138

IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts.

R Chizzonite1, T Truitt, B B Desai, P Nunes, F J Podlaski, A S Stern, M K Gately.   

Abstract

IL-12 is a 75-kDa heterodimeric cytokine composed of disulfide-bonded 35-kDa and 40-kDa subunits. Included among the biologic activities mediated by IL-12 is induction of proliferation of PHA-activated human PBL. The concentration of IL-12 required to stimulate maximum proliferation of PHA-activated lymphoblasts is 50 to 100 pM. In this study, highly purified 125I-labeled IL-12 (7 to 15 microCi/microgram; 50 to 100% bioactive) was used to characterize the receptor for IL-12 on 4-day PHA-activated lymphoblasts. The binding of 125I-labeled IL-12 to PHA-activated lymphoblasts was saturable and specific because the binding of radiolabeled ligand was only inhibited by IL-12 and not by other cytokines. The kinetics of [125I]IL-12 binding to PHA-activated lymphoblasts was rapid at both 4 degrees C and 22 degrees C; reaching equilibrium within 60 min. At 22 degrees C, the rate of dissociation of [125I]IL-12 was slow in the absence of competing IL-12 (t1/2 = 5.9 h) and more rapid in the presence of 25 nM competing IL-12 (t1/2 = 2.5 h). The kinetically derived equilibrium dissociation constant ranged from 10 to 83 pM. Analysis of steady state binding data by the method of Scatchard identified a single binding site with an apparent equilibrium dissociation constant of 100 to 600 pM and 1000 to 9000 sites/lymphoblast. The equilibrium dissociation constant for competing ligands and sites per cell calculated from unlabeled IL-12 competition experiments ranged from 164 to 315 pM and 1067 to 3336, respectively, which is in good agreement with the values determined from steady state binding. The variations in KD and sites per cell were dependent on the individual preparations of lymphoblasts. Although the steady state binding data were consistent with a single class of high affinity binding sites, the kinetic dissociation data indicates a cooperative interaction between receptors on PHA-activated lymphoblasts. Affinity cross-linking of surface bound [125I]IL-12 to PHA-activated lymphoblasts at 4 degrees C identified a major complex of approximately 210 to 280 kDa. Anti-IL-12 antibodies also immunoprecipitated a complex of approximately 210 to 280 kDa that was produced by cross-linking unlabeled IL-12 to 125I-labeled lymphoblast cell-surface proteins. Cleavage of this complex with reducing agent identified one radiolabeled protein of approximately 110 kDa. These data suggest that the IL-12 binding site on PHA-activated lymphoblasts may be composed of a single protein of approximately 110 kDa.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1578138

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP.

Authors:  Wanda Niedbala; Xiao-Qing Wei; Carol Campbell; Duncan Thomson; Mousa Komai-Koma; Foo Y Liew
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-25       Impact factor: 11.205

2.  Timescale analysis of rule-based biochemical reaction networks.

Authors:  David J Klinke; Stacey D Finley
Journal:  Biotechnol Prog       Date:  2011-09-26

3.  Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Authors:  D Zagury; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Inferring relevant control mechanisms for interleukin-12 signaling in naïve CD4+ T cells.

Authors:  Stacey D Finley; Deepti Gupta; Ning Cheng; David J Klinke
Journal:  Immunol Cell Biol       Date:  2010-05-18       Impact factor: 5.126

5.  The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis.

Authors:  Catherine E Steding; Sung-tse Wu; Yanping Zhang; Meei-Huey Jeng; Bennett D Elzey; Chinghai Kao
Journal:  Immunology       Date:  2011-04-01       Impact factor: 7.397

6.  Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.

Authors:  K E Balashov; D R Smith; S J Khoury; D A Hafler; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 7.  IL12Rβ1: the cytokine receptor that we used to know.

Authors:  Richard T Robinson
Journal:  Cytokine       Date:  2014-12-13       Impact factor: 3.861

8.  Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.

Authors:  J M Péron; C Bureau; P Gourdy; H Lulka; A Souque; B Calippe; J Selves; T Al Saati; J Bernad; P Cordelier; B Couderc; L Pradayrol; B Pipy; L Buscail; J P Vinel
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

9.  Interleukin 12: a potential link between nerve cells and the immune response in inflammatory disorders.

Authors:  L A Turka; R E Goodman; J L Rutkowski; A A Sima; A Merry; R S Mitra; T Wrone-Smith; G Toews; R M Strieter; B J Nickoloff
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

Review 10.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.